LOIM
PRVB

Liberty One Investment Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Liberty One Investment Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,200
Closed -$139K – 143
2021
Q1 		$139K Buy
13,200
+5,620
+74% +$79.1K 0.02% 140
2020
Q4 		$128K Buy
7,580
+2,048
+37% +$30.7K 0.02% 118
2020
Q3 		$71K Buy
5,532
+2,714
+96% +$34.3K 0.01% 126
2020
Q2 		$40K Buy
+2,818
New +$35.6K 0.01% 127

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Liberty One Investment Management's PRVB Position: Q2 2021 in Review

Liberty One Investment Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2021, closing a stake of 13,200 shares — an estimated $139K sold.

Liberty One Investment Management first reported a position in PRVB in Q2 2020 and held it in 4 quarters. The position peaked at $139K in Q1 2021. 125 funds tracked by Wall St. Rank hold PRVB as of Q2 2021.

  • Liberty One Investment Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Liberty One Investment Management sold 13,200 Provention Bio, Inc. Common Stock shares in Q2 2021, an estimated $139K.
  • Liberty One Investment Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Liberty One Investment Management's Provention Bio, Inc. Common Stock position peaked at $139K in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2021.

Based on Liberty One Investment Management's 13F filing for Q2 2021, filed 20 Jul 2021.